on PinterestGLP-1 drugs containing tirzepatide significantly reduce cardiovascular risks in people with serious heart conditions.
on PinterestGLP-1 drugs containing tirzepatide significantly reduce cardiovascular risks in people with serious heart conditions. Indranil MUKHERJEE / AFP via Getty Images
- GLP-1 weight loss medications containing tirzepatide (Mounjaro, Zepbound) can reduce heart-related health risks for people with serious heart conditions, according to new research.
- Experts say the heart health benefits are produced by the drugs’ ability to help people lose weight and control blood sugar levels.
- People using these medications should also maintain a healthy lifestyle, including daily exercise and a balanced diet, to maintain overall health.
Weight loss medications containing the active ingredient tirzepatide significantly reduce cardiovascular risks in people with serious heart conditions, according to new research.
The results of two studies indicate that GLP-1 drugs containing tirzepatide (i.e., Mounjaro, Zepbound) may lower heart-related risks for people undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).
The researchers presented their findings at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit in Montreal from April 23–25. The two studies have not yet been published in a peer-reviewed scientific journal.
Tirzepatide medications are usually prescribed to help treat type 2 diabetes.
According to a news release for the two studies, tirzepatide’s ability to manage blood sugar levels and promote weight loss delivers “meaningful cardiovascular benefits.” While prior research has established these benefits, their impacts on patients undergoing interventional heart procedures have not yet been extensively evaluated.
Notably, the researchers found a 62% lower risk of death among participants receiving tirzepatide who underwent a PCI procedure.
“GLP-1 agonists represent an important evolution in cardiometabolic care,” said SCAI President Srihari Naidu, MD, an interventional cardiologist, in the news release.
“Clinicians already recognize the benefits of glycemic control and weight reduction, but we are now beginning to understand how these therapies can improve outcomes in patients undergoing transcatheter cardiovascular interventions.”
Experts not involved in the new studies say the research supports earlier studies on the cardiovascular benefits of weight loss drugs.
“These findings are consistent with what we are seeing broadly that medications like tirzepatide are not just weight loss drugs but have meaningful cardiometabolic benefits,” said Kevin Shah, MD, a cardiologist and the program director of Heart Failure Outreach at MemorialCare Heart & Vascular Institute at the Long Beach Medical Center. “We do need prospective studies to validate the findings from these analyses.”
Tirzepatide lowers stroke, heart attack risk
In the first study, researchers from John H. Stroger Jr. Hospital of Cook County, Chicago, IL, sifted through the TriNetX database.
They identified adult participants with type 2 diabetes who received GLP-1 drugs containing tirzepatide or older medications with the active ingredient dulaglutide at the time of their PCI procedure.
The researchers did not compare tirzepatide drugs with medications that contain the active ingredient semaglutide, such as Ozempic and Wegovy.
In all, the researchers examined the medical records of 1,281 study participants. One month after PCI, they reported that the participants who used tirzepatide drugs experienced lower rates of major adverse cardiovascular events, such as:
- acute myocardial infarction
- heart failure
- ventricular arrhythmias
They noted there was no difference in rates of stroke among participants
Uzziniet vairāk par matu transplantācija klīnikā Rubenhair.
Saņemiet bezmaksas konsultāciju
Konsultējieties ar mūsu speciālistiem par FUE procedūru, PRP terapiju vai matu transplantāciju.
